Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777655 | 0.96 | CTRB1 (0.46) | CTRB1F2KMT2AMDM4TP53 | |
| SCHEMBL31501508 | 0.96 | CTRB1 (0.46) | CTRB1F2KMT2AMDM4TP53 | |
| SCHEMBL30688537 | 0.92 | CTRB1 (0.44) | CTRB1F2KMT2AFDFT1NPSR1 | |
| SCHEMBL29706288 | 0.91 | CTRB1 (0.55) | CTRB1F2KMT2AMDM4TP53 | |
| SCHEMBL29868206 | 0.90 | CTRB1 (0.56) | CTRB1F2KMT2AHSD17B10 | |
| SCHEMBL6434028 | 0.90 | CTRB1 (0.56) | CTRB1F2KMT2AHSD17B10 | |
| SCHEMBL29858987 | 0.89 | CTRB1 (0.46) | CTRB1F2KMT2AMDM4TP53 | |
| SCHEMBL29566581 | 0.89 | CTRB1 (0.46) | CTRB1F2KMT2AMDM4TP53 | |
| SCHEMBL29467321 | 0.88 | F2 (0.45) | F2KMT2AMDM4TP53FDFT1 | |
| SCHEMBL29750784 | 0.88 | ACE (0.45) | CTRB1F2FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039418-A | Preparation method of Tirzepatide | 江苏慧聚药业股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-114989313-B | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 福建亿彤生物科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-114989313-A | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 亿彤科技发展(福建)有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-119431491-A | Synthesis method of Fmoc-Xaa-Ser (Psi (Me, me) Pro) -OH pseudo dipeptide | 杭州湃肽生化科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119039418-A | Preparation method of Tirzepatide | 江苏慧聚药业股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-117866074-A | Method for preparing teicoplanin by solid-liquid phase combination | 瑞博(苏州)制药有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114989313-B | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 福建亿彤生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-07 | — | — | US | disclosed |
| CN-117106093-A | Double Fmoc-protected Tirzepatide backbone 39 peptide and synthesis method and application thereof | 上海多米瑞生物技术有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4242219-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116171164-A | GLP-1/GIP dual agonists | 太阳医药工业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115768460-A | Long-acting GLP-1/GIP dual agonists | 太阳医药工业有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114989313-A | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 亿彤科技发展(福建)有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114790236-A | Synthetic method of GCGR/GLP-1R double-target-point agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, DNPEP, NPPA | CTRB1 2754/4885F2 3183/4885KMT2A 2159/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | CTRB1 3178/4885F2 3694/4885KMT2A 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.